Sclerostin neutralization unleashes the osteoanabolic effects of Dkk1 inhibition

The WNT pathway has become an attractive target for skeletal therapies. High-bone-mass phenotypes in patients with loss-of-function mutations in the LRP5/6 inhibitor Sost (sclerosteosis), or in its downstream enhancer region (van Buchem disease), highlight the utility of targeting Sost/sclerostin to...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JCI Insight
Main Authors: Witcher, Phillip C., Miner, Sara E., Horan, Daniel J., Bullock, Whitney A., Lim, Kyung-Eun, Kang, Kyung Shin, Adaniya, Alison L., Ross, Ryan D., Loots, Gabriela G., Robling, Alexander G.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Clinical Investigation 2018
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6124404/
https://ncbi.nlm.nih.gov/pubmed/29875318
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.98673
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados